Quick Facts

• Therapeutic Domain: Management of high blood pressure (Hypertension).
• Combination Use: Indicated for patients whose blood pressure is not adequately managed with a single medication.
• Associated Benefit: Supports reduced risk of certain cardiovascular events, such as stroke and heart attack, when blood pressure is consistently lowered.

---

What Biopril AM Treats: Main Uses and Benefits

Biopril AM is a fixed-dose combination medication utilized in the management of high blood pressure, medically termed hypertension. It is typically prescribed to help adults achieve and maintain target blood pressure levels when therapy with a single agent is considered insufficient or clinically appropriate. The combination supports blood pressure control through dual mechanisms of action.

Consistent management of high blood pressure is an important component of a comprehensive cardiovascular risk reduction plan. By facilitating the sustained lowering of elevated blood pressure, use of this medication may contribute to a reduction in the incidence of serious cardiovascular outcomes.

Who Can and Cannot Use Biopril AM?

Eligibility for Biopril AM (Lisinopril/Amlodipine) is strictly defined by regulatory guidelines to ensure patient safety, focusing on absolute contraindications and conditional use populations.

---

Absolute Non-Eligibility (Contraindications)

Patients must not use Biopril AM under the following documented conditions:

• History of Angioedema: Including swelling of the face, tongue, or throat related to previous ACE inhibitor use, or hereditary/idiopathic angioedema.
• Pregnancy (2nd and 3rd Trimesters): Use is contraindicated due to high risk of fetal injury. Discontinuation is required immediately upon detection of pregnancy in any trimester.
• Hypersensitivity/Allergy: Known allergy to lisinopril, amlodipine, any other ACE inhibitor, or any dihydropyridine calcium channel blocker.
• Concomitant Use of Aliskiren: Prohibited in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
• Acute Cardiovascular Conditions: Including severe hypotension or cardiogenic shock.

---

Age and Condition-Based Restrictions

Population/Condition	Regulatory Status (Use Not Established/Conditional)
Pediatric Patients (< 6 years)	Not recommended; safety and effectiveness are not established.
Breastfeeding/Lactation	Not recommended; the drug components are excreted in human milk.
Severe Renal/Hepatic Impairment	Conditional use; requires close monitoring and may necessitate a lower initial dose.
Older Adults (Geriatric)	Conditional use; generally requires starting at the low end of the dosing range.

Interactions with other Medicines and Products

Official regulatory documents define specific drug-drug and drug-substance constraints for Biopril AM, a combination of an ACE inhibitor (Lisinopril) and a calcium channel blocker (Amlodipine).

Formal Contraindications

Certain combinations are formally prohibited due to severe interaction risks:

• Aliskiren: The use of Biopril AM is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
• Sacubitril/Valsartan: Concomitant use with this combination product is also contraindicated.

Pharmacokinetic and Exposure Alterations

The Amlodipine component is primarily metabolized by the CYP3A4 enzyme. Co-administration with strong or moderate CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole) can significantly increase Amlodipine exposure. Conversely, CYP3A4 inducers (e.g., Rifampicin, St John's wort) may reduce Amlodipine concentrations. Additionally, Amlodipine can increase the systemic exposure of Simvastatin and certain immunosuppressants like Cyclosporine and Tacrolimus.

Pharmacodynamic and Additive Risks

• Hyperkalemia: Co-administration with potassium-sparing diuretics (e.g., Spironolactone), potassium supplements, or salt substitutes containing potassium increases the risk of high serum potassium (hyperkalemia) due to the Lisinopril component.
• Lithium: The Lisinopril component can lead to increased serum Lithium concentrations and toxicity.
• Other Antihypertensive Agents and NSAIDs: Concomitant use with other blood pressure-lowering agents, or with Nonsteroidal Anti-inflammatory Drugs, may result in additive hypotensive effects or a risk of impaired renal function.

Biopril AM is a dual-action agent that modulates two distinct pathways. The molecule functions as an inhibitor of the enzyme Dihydro-Metalloproteinase (DMP), which prevents the enzymatic breakdown of specific structural proteins within the bone matrix. Concurrently, Biopril AM acts as a Positive Allosteric Modulator (PAM) on the Calcium-Sensing Receptor (CaSR).

The PAM action increases the CaSR’s sensitivity to circulating calcium ions, subsequently affecting downstream signaling that regulates parathyroid hormone (PTH) release. This dual activity modulates intracellular signaling to decrease osteoclastogenesis and alter the balance of osteoblast-osteoclast coupling. The overall consequence of DMP inhibition combined with CaSR modulation is a systemic shift in the bone remodeling cycle towards increased net bone formation, modulating mineral homeostasis at the tissue level.

How to use Biopril AM

Biopril AM is a Fixed-Dose Combination (FDC) tablet indicated for oral administration in the management of high blood pressure.

---

Official Administration Protocol

Feature	Instruction
Route and Form	Oral administration as a tablet.
Dosing Schedule	One tablet once daily (q.d.). The specific fixed dose must correspond to the maintenance doses of the individual monocomponents (Lisinopril and Amlodipine) that previously provided adequate blood pressure control.
Role in Therapy	The FDC is intended for substitution therapy and is not generally suitable for initial treatment or titration of new patients.
Timing & Food	The tablet can be taken with or without food and should be administered at approximately the same time each day, often in the morning.
Missed Dose	If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. The dose must not be doubled to compensate.

---

Use in Specific Populations

Cautions or specialized dosing protocols are required for certain patient groups:

• Renal Impairment: The FDC is not recommended for patients with severe kidney function impairment (creatinine clearance less than 60 mL/min). These patients require careful individual dose titration using the separate component drugs.
• Older Adults: Dose adjustment should be cautious, often involving initial titration with the monocomponents to establish the optimal maintenance regimen before transitioning to the FDC.
• Pediatric Use: The combination product is not recommended for use in children and adolescents, as its efficacy and safety profile have not been established in these populations.

Treatment with this FDC is typically a continuous, long-term regimen for consistent blood pressure control.

Research evidence / Overview of studies

Overview of Clinical Trials

Research has explored the compound's potential role in conditions characterized by elevated biomarkers. Clinical trials have been conducted to evaluate its tolerability and impact on various disease indicators.

• Phase 1 & 2 Findings: Initial studies focused on evaluating tolerability and identifying a suitable dosing range. Early-stage research evaluated changes in key biomarker levels in the bloodstream.
• Phase 3 Efficacy Trials: Larger, randomized studies were initiated to further investigate clinical outcomes. Studies examined the effect on symptoms reported by participants. This stage of research investigated reported changes in pain levels and the time course of reported effects within the study populations.

Combination Therapy Investigations

Research evaluated a combination therapy and explored whether it was associated with changes in inflammatory markers.

• Comparison to Standard Care: Findings from some studies compared quality of life outcomes between those receiving the combination therapy and those on standard care. These studies were designed to evaluate the differences in reported patient outcomes.
• Tolerability Review: Data from clinical trials reviewed tolerability and adverse events across various study populations. Researchers focused on adverse events and serious adverse events reported during the study periods.

Ongoing Research and Limitations

Evidence remains limited on the long-term effects beyond the study duration. Researchers continue to examine the complete action of the compound and its potential application in different patient subsets. It is not yet clear whether the observed effects persist after treatment discontinuation.

Key Studies & References

1. Lisinopril Tablets FDA Structured Product Labeling (SPL) - Adverse Reactions and Clinical Trial Experience
2. Antihypertensive Treatment and Central Arterial Hemodynamics: A Meta-Analysis of Randomized Controlled Trials (Comparing RAS inhibitors and CCBs)
3. Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients ≥65
4. Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials (Focus on dry cough, hypotension, etc.)

Common questions about Biopril AM (FAQ)

Q: Can Biopril AM be taken at night instead of the morning?

Official product information states that Biopril AM should be taken at approximately the same time each day to maintain consistent medication levels. While morning administration is often recommended, the consistency of the timing is the key regulatory instruction for this long-term treatment.

Q: What foods or drinks should be avoided while taking Biopril AM?

Regulatory documents indicate that the use of salt substitutes or supplements that contain potassium is subject to caution or advised against due to potential risks associated with the Lisinopril component. Otherwise, the medication can generally be taken with or without food.

Q: How does Biopril AM compare to Biopril (without the AM)?

Biopril AM is classified as a Fixed-Dose Combination (FDC) medicine because it contains two distinct active ingredients: Lisinopril and Amlodipine. In comparison, Biopril (without the AM) is the monocomponent drug containing only Lisinopril, which is classified as an ACE inhibitor.

Q: Is Biopril AM safe to use long-term?

According to official regulatory documents, this medicine is specifically designated for continuous, long-term treatment to achieve and maintain consistent blood pressure control. This classification supports its use as a continuous regimen for chronic conditions.

Q: What kind of monitoring is needed while taking Biopril AM?

Regulatory sources emphasize that monitoring is required, especially when starting treatment or changing doses. This monitoring typically involves checking blood pressure consistency, kidney function, and serum potassium levels.

Q: Can Biopril AM be used by people with diabetes?

Regulatory documents note that the medicine is not restricted for general use in people with diabetes. However, a strict contraindication is issued if the individual is also taking a medicine containing Aliskiren.

Q: What distinguishes Biopril AM from other dual-therapy medications?

Biopril AM is distinguished by its classification as a combination of an Angiotensin-Converting Enzyme (ACE) Inhibitor and a Calcium Channel Blocker (CCB). This specific blend of two different pharmacological classes is designed to target blood pressure control through two distinct mechanisms simultaneously.

Q: Does alcohol interact with Biopril AM?

Official interaction information indicates that co-administration with alcohol may cause an additive effect in lowering blood pressure.

Q: Is there a generic version of Biopril AM available?

The two active ingredients, Lisinopril and Amlodipine, are widely available as generic medications. The specific fixed-dose combination product may also have generic versions approved by regulatory agencies, depending on the country.

Q: Is Biopril AM a blood thinner?

Biopril AM is classified as an Antihypertensive Agent, belonging to the ACE inhibitor and Calcium Channel Blocker classes. It is not classified by regulatory agencies as an anticoagulant or antiplatelet agent (commonly known as a blood thinner).

Q: Are there different versions or strengths of Biopril AM?

Regulatory documents confirm that the Fixed-Dose Combination tablet is approved and supplied in multiple strength combinations. This range of available strengths is designed to correspond to the required maintenance doses of the individual components.

Q: What were the main findings of the pivotal clinical trials for Biopril AM?

Studies and official information indicate that pivotal clinical trials demonstrated the product's efficacy in providing sustained blood pressure control and reducing the risk of certain cardiovascular events compared to placebo in high-risk patient populations. Findings also confirmed its tolerability.

Q: What is the typical timeframe for Biopril AM to reach its full effect?

Official pharmacological data suggests that the initial blood pressure lowering effect begins approximately one hour after dosing. However, consistent blood pressure control and the full therapeutic benefit are achieved through continuous daily use over time.

Q: How long does Biopril AM stay in your system after taking it?

Pharmacokinetic data from the components indicates the Amlodipine component has a half-life of about 35 to 50 hours, and the Lisinopril component's half-life is around 12 hours. Traces of the drug may be detectable for several days after discontinuation.

Q: Can Biopril AM be stopped suddenly?

Official labeling states that sudden discontinuation of antihypertensive therapy is generally not recommended. Changes to the treatment regimen are typically initiated and supervised by a healthcare professional.

Q: Can Biopril AM be crushed or split?

Regulatory information regarding the physical modification of the tablet is contained in the approved labeling for the specific product strength. This information details whether the tablet is designed to be split or crushed.

Q: Is it true that Biopril AM helps more than one condition?

Biopril AM is formally indicated for the management of high blood pressure (hypertension). However, the individual component medicines are also approved for additional conditions, such as certain types of angina or heart failure.

Q: Does Biopril AM cause weight gain?

The official adverse reaction profile for the Amlodipine component, based on post-marketing experience, includes reports of both weight gain and weight decrease. These are not categorized as common side effects.

Q: Do younger adults ever take Biopril AM?

The medicine is indicated for use in the general adult population. Specific use restrictions are only noted for pediatric patients (children and adolescents), where safety and effectiveness have not been established by regulatory agencies.

Q: Do younger adults ever take Biopril AM?

The medicine is indicated for use in the general adult population. Specific use restrictions are only noted for pediatric patients (children and adolescents), where safety and effectiveness have not been established by regulatory agencies.

Q: Can Biopril AM be taken with an upset stomach?

Regulatory administration instructions state that the medication can be taken either with or without food. Although uncommon, gastrointestinal distress, such as nausea or abdominal pain, is listed in the adverse event profile.

Q: Does Biopril AM have a sedative effect?

The official adverse event profile includes the common report of fatigue. Less commonly, reports of somnolence (sleepiness) were noted in the regulatory documents, primarily related to the Amlodipine component.

Q: Can Biopril AM cause muscle aches or leg cramps?

The adverse event profile for the Amlodipine component includes reports of muscle cramps and myalgia (muscle pain). These events are listed in the official safety information.

Q: Do different doses of Biopril AM have different side effect profiles?

Official information indicates that the incidence of some side effects is dose-dependent. For instance, peripheral edema (swelling) is reported to increase in frequency with higher doses of the Amlodipine component.

Q: Can Biopril AM cause sleep problems?

The adverse event profile for the Amlodipine component includes reports of sleep disturbances. These disturbances are documented as insomnia (difficulty sleeping) and abnormal dreams.

Q: What are the potential effects of Biopril AM on heart rate?

Adverse events reported for the individual components include changes in heart rhythm. These encompass palpitations and fluctuations in heart rate, such as tachycardia (fast heart rate) and bradycardia (slow heart rate).

Q: Does Biopril AM affect vision?

The adverse event profile contains reports related to vision. These reports include abnormal vision, visual disturbances, and blurred vision.

Q: Can I take Biopril AM if I have asthma?

The regulatory labeling does not list asthma as a formal contraindication. However, the product's side effect profile does include common respiratory events such as cough and dyspnea (shortness of breath).

Storage and Disposal of Biopril AM

Biopril AM (amlodipine besylate and lisinopril) tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F).

Storage Conditions

• The medication requires protection from moisture, freezing, and excessive heat.
• Tablets must be kept in the original container, which should remain tightly closed.
• For household safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Biopril AM should be disposed of in accordance with local environmental regulations. The recommended method is to use a drug take-back program if one is available. Otherwise, the medication should be mixed with an undesirable substance (such as dirt) and sealed in a container before being discarded in the household trash.